This finding suggests that TMZ, as a ligand, can bind to the ligand-binding pockets of ARMC10, and this binding results in deficiency in the concentration of TMZ in patients with glioma who undergo TMZ chemotherapy. This evidence concerns the gene ARMC10 and central nervous system cancer.